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ABSTRACT
Host defense peptides (HDPs) are naturally occurring molecules found in most 
species, in which they play a significant role in the first line defense against intruding 
pathogens, and several HDPs have been shown to possess anticancer activity. 
Structure-activity relationship studies on the HDP bovine lactoferricin revealed 
a de novo design of a nonamer peptide LTX-315, with oncolytic properties.
In the present study, we investigated the oncolytic activity of LTX-315 in human 
melanoma cells (A375). LTX-315 induced a rapid plasma membrane disruption and 
cell death within 2 hours. At a low concentration, fluorescence-labeled LTX-315 
was internalized and accumulated in cytoplasmic vacuoles in close proximity to the 
mitochondria. The mitochondrial membrane potential was shown to depolarize as 
a consequence of LTX-315 treatment and at ultrastructural level, the mitochondria 
morphology was significantly altered. Release of danger signals (DAMPs) such as 
ATP, Cytochrome C and HMGB1 into the cell supernatant of cultured cells was evident 
minutes after peptide treatment.
The oncolytic effect of LTX-315 involving perturbation of both the cell membrane 
and the mitochondria with subsequent release of DAMPs may highlight the ability of 
LTX-315 to induce complete regression and long-term protective immune responses 
as previously reported in experimental animal models.
INTRODUCTION
Host defense peptides (HDPs) represent a diverse 
group of peptides found in virtually all species of life as a 
part of the innate immune system [1, 2]. In addition to the 
bactericidal effects, many HDPs have been shown to have 
antitumor [3] and antiviral [4] activity, and contribute to 
both innate and adaptive immunity [5, 6]. The host defense 
peptide lactoferricin (LfcinB) is a cyclic 25-amino acid 
peptide widely investigated for both its antimicrobial 
properties, as well as for antitumor effect, in vitro and 
in vivo [7–9]. Based on extensive structure-activity studies 
performed on LfcinB, we have identified several structural 
parameters critical to its anti-tumor activity and selectivity 
[10–12]. With an optimization of these parameters, a new 
group of shorter and more potent anticancer peptides has 
been designed. One of these, LTX-302, was reported 
to rapidly induce necrosis in murine cancer cells [13]. 
Interestingly, LTX-302 treatment also induced a complete 
regression and subsequent protection against re-challenge 
in an experimental animal model by inducing an adaptive 
immune response [13]. We have recently reported 
anticancer effects of the nonamer LTX-315 (Figure 1) [14, 
15], which is considerably shorter than the model peptide 
LfcinB (25aa). LTX-315 has the ability to adopt a α-helical 
secondary structure and contains five cationic Lys 
residues, three Trp residues, the bulky non-coded residue 
β-diphenylalanine (Dip) and an amidated C-terminal. This 
peptide has been shown to rapidly induce necrosis and 
anticancer immune responses after intratumoral treatment 
in an experimental murine melanoma model [14, 15]. 
Given the strong immunomodulatory effect of LTX-315 
observed in vivo, we wanted to investigate the mechanisms 
of action of LTX-315 in human melanoma cells in vitro.
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RESULTS
Cytotoxic effect of LTX-315 on melanoma cells
The cytotoxic activity of LTX-315 on A375 melanoma 
cells was investigated at different time points. The IC50 
values determined at each time point show that LTX-315 
killed the cancer cells within minutes. (Figure 2)
The IC50 value for LTX-315 was 30 μM after only five 
minutes of exposure and lowered to 17 μM after 60 minutes.
LTX-315 treatment causes rapid cell lysis
We next wanted to assess the cell morphology of 
A375 melanoma cells after being treated with LTX-315. 
Cells were treated in a time dependent manner with LTX-
315 (17 μM) and investigated by bright field confocal 
microscopy. Treated cells displayed a rapid change from 
a normal epithelial morphology to a total collapse of the 
cells with an extrusion of cytoplasmic content, which 
was proceeded by a rounding up of the cell (Figure 3). 
These changes occurred in the majority of cells within 
15–60 minutes of treatment with LTX-315. A time-lapse 
movie showing the morphological changes in treated 
cells is enclosed in the supplementary section.
LTX-315 rapidly induced loss of plasma 
membrane integrity
To further investigate the membranolytic activity 
of LTX-315, treated cells were labeled with the DNA 
binding fluorescent probe PI. This dye is commonly used to 
distinguish between live and necrotic cells in various assays 
as it only enters cells with a compromised plasma membrane. 
To elucidate if the initial membranolytic effect was 
dependent on internalization of the peptide we conducted the 
following experiments at 4°C and 37°C respectively. Live 
cell imaging with confocal microscopy demonstrated that 
treatment LTX-315 for 5 minutes was sufficient to induce 
loss of plasma integrity in a majority of cells at both 4°C and 
37°C (Figure 4 A–4D). Hence, the membranolytic activity 
by LTX-315 is not dependent on endocytosis or other types 
of active transportation mechanism.
LTX-315 internalizes and targets the 
mitochondria
To investigate if LTX-315 is internalized and has 
any intracellular targets, A375 cells were incubated with 
Pacific Blue-labeled LTX-315. The labeled LTX-315 
rapidly penetrated the plasma membrane and showed 
an accumulation close to the mitochondria after 30 
minutes of incubation without being detected in the cell 
nucleus (Figure 5). The labeled non-lytic mock-sequence 
peptide LTX-328 did not demonstrate any internalization 
at any concentration or incubation time tested 
(Figure 6B). LTX-315 treated A375 cells also showed 
a decreased signal from the mitochondrial membrane 
potential sensitive dye Mitotracker. (Figure 7), indicating 
that LTX-315 interacts with the mitochondria membrane.
LTX-315 induces ultra-structural changes in 
cells
We further evaluated the ultra-structural changes 
in A375 cells after LTX-315 treatment by performing 
transmission electron microscopy (TEM). A significant 
number of the cells treated with a low concentration of 
the LTX-315 peptide (3,5 μM) for 60 minutes showed 
vacuolization, as well as altering of the mitochondrial 
morphology (Figure 8B). The mitochondria appeared 
to be less electron-dense, also exhibiting some degree 
of reorganization, with the cristae lying further apart 
or not visible at all. This in contrast to electron dense, 
Figure 1: Chemical structure of LTX-315 (K-K-W-W-K-K-W-Dip-K-NH2) generated using ChemDraw 11. Dip is the 
aromatic non-coded amino acid β-diphenylalanine. 
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normal appearing mitochondria of the untreated cells. 
(Figure 8A and 8D) The number of necrotic cells in 
these samples was less than 5%. Moreover, perinuclear 
vacuoles were also observed at low concentration of LTX-
315, with a content consisting of cytosolic material such 
as ribosomes and other organelles (Figure 8E). Another 
common finding in these samples were peripherally placed 
vacuoles, which were lined with a single membrane layer 
containing a homogenous material (Figure 8B). When 
cells were treated with a higher concentration (17 μM) for 
60 min, approximately 40% of them displayed a necrotic 
morphology with a loss of plasma membrane integrity 
(Figure 8C). The cells that were still intact displayed a 
great heterogeneity, from a normal appearance with 
microvilli to a round appearance, with mitochondria 
clearly affected. At this high concentration, only 4% 
of the cells investigated displayed vacuolization, and 
chromatin condensation was not visible in the cells at any 
peptide concentration tested. These results demonstrate 
that LTX-315 kills the tumor cells with a lytic mode 
of action, while lower concentrations cause the cells to 
undergo ultrastructure changes, such as vacuolization 
and an altered mitochondrial morphology. No significant 
morphological changes suggestive of apoptotic cell death 
were observed.
LTX-315 treatment leads to extracellular ATP 
release
Danger-associated molecular pattern molecules 
(DAMPs) are molecules that are released from intracellular 
sources during cellular damage. DAMPs can initiate and 
perpetuate an immune response through binding to Pattern 
Recognition Receptors (PRRs) on Antigen Presenting 
Cells (APCs). Among commonly known DAMPs are 
ATP, HMGB1, Calreticulin, Cytochrome C, mitochondrial 
DNA and Reactive oxygen species (ROS) [18–20]. We 
investigated release of several DAMPs including the level 
of ATP released into the supernatant from cells treated 
with LTX-315. (35 μM) The supernatant from treated and 
non-treated cells was diluted at 1:10 and analyzed using 
luciferase detection assay. As shown in Figure 9, ATP was 
detected in the supernatant as early as after 5 minutes of 
treatment with LTX-315.
Figure 3: LTX-315 kills human melanoma cells in a lytic mode of action. Bright field confocal images of A375 cells treated 
with 17 μM LTX-315. A. 1 min after added peptide, B. 22 min after added peptide, C. 65 min after added peptide, D. 65 min after added 
peptide (12.5s after c)
Figure 2: LTX-315 causes rapid cell death in human melanoma cells. In vitro cell killing kinetics of LTX-315 (IC50) against 
human melanoma cells after designated time points.
Oncotarget34913www.impactjournals.com/oncotarget
LTX-315 treatment induces cytochrome-C 
release in supernatant
To assess whether LTX-315-treated cells released 
cytochrome-C into the medium, A375 cells were treated 
with LTX-315 35 μM at different time points (5, 15, 
45 min). The supernatant was subsequently analyzed for 
cytochrome-C levels using an ELISA assay. Cell cultures 
treated with 35 μM had a 3-fold increase of cytochrome-C 
in the supernatant compared to untreated control cells. 
The increase in cytochrome-C was detected already at 
five minutes of exposure with LTX-315. (Figure 10).
Figure 4: LTX-315 decrease plasma membrane integrity independent of temperature; A375 cells treated with 
35 μM LTX-315 and labelled with PI (red) and nuclear dye Hoechst 33342 (blue) was investigated using confocal 
microscopy. A. untreated cells at 37°C, B. treated cells at 37°C, C. ) untreated cells at 4°C, D. treated cells at 4°C. 
Figure 5: LTX-315 internalizes and accumulates close to the mitochondria. A375 cells were transfected with fluorescent 
organelle markers. The mitochondria were labeled using the pDsRed2-Mito, and the nucleus was labeled using the GFP-Histon2B plasmid, 
prior to treatment with fluorescence labeled LTX-315 peptide (Pacific Blue). Transfected cells were treated 30 minutes with 1,5 μM 
fluorescence-labeled LTX-315 (green), and with labeled mitochondria (red) and nucleus (blue pseudo color). The peptide was internalized 
and detected in close proximity to the mitochondria. A. overlay channels, B. close up, C. mitochondria. D. LTX-315.
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LTX-315 treatment leads to extracellular 
HMGB1 release
When the nuclear protein HMBG1 is released into 
the extracellular fluid, it functions as a DAMP, and can 
bind to both the PRR TLRs and to the RAGE receptors; 
whose activation leads to a number of inflammatory 
responses such as activation and maturation of antigen 
presenting cells (APCs). In order to assess the release of 
HMGB1 from LTX-315-treated cells, we measured the 
translocation of HMGB1 from the nuclear compartment 
into the culture supernatant [18]
Both cell lysate and the cell supernatant of LTX-
315- and LTX-328-treated A375 melanoma cells were 
analyzed using a western blot. Cells were treated with 
35 μM of either LTX-315 or LTX-328, and a gradual 
increase in translocation of HMGB1 from the cell lysate 
to the supernatant was detected in the LTX-315-treated 
melanoma cells, but not in the supernatants of cells treated 
with the mock sequence peptide LTX-328 or a serum-free 
medium only (Figure 11).
LTX-315 treatment causes the production 
of Reactive Oxygen Species (ROS) in A375 
melanoma cells
Reactive Oxygen Species (ROS) have been reported 
to play important roles in immunogenic cell death [19, 20], 
and one important source of ROS can be dysfunctional 
mitochondria [21, 22]. It has also been implied to 
decrease the immunogenicity of released HMGB1 by 
oxidation [23]. The ROS generation following LTX-315 
Figure 6: Internalization occurs only in labeled LTX-315 and not in the labeled mock peptide LTX-328. A375 cells 
treated with 35 μM LTX-315 A. or LTX-328 B. peptide for 60 min. Fluorescence-labeled peptide (green), and with labeled mitochondria 
(red) and nucleus (blue pseudo color). LTX-315 was detected in the cytoplasm, while LTX-328 was not internalized.
Figure 7: LTX-315 causes decreased mitochondrial membrane potential. A375 cells treated with 17 μM LTX-315 for 60 min 
were subsequently labelled with Mitotracker. A lower signal was detected in the treated cells B. as compared with untreated cells A. (Z-stack, 
maximum intensity projection)
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Figure 8: Ultrastructural changes in cells treated with LTX-315. TEM images of A375 cells treated with LTX-315 for 60 minutes 
compared to control cells. A. D: untreated control cells, B. E.: cells treated with 3,5 μM, C., F. cells treated with 17 μM, arrowhead indicate 
cell with disintegrated plasma membrane, N indicate nucleus. Magnification 10 000X A-C, 30 000 D-F.
Figure 9: Extracellular ATP levels following LTX-315 treatment. A375 cells were treated with LTX-315 (35 μM) for different 
time point or maintained under controlled conditions, and supernatant analyzed for the quantification of ATP secretion by luciferase 
bioluminescence. Quantitative data (mean +- S.D.) for one representative experiment are reported.
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treatment was measured by CH2DCFDA fluorometric 
assay. An increase in ROS production was generated after 
15 minutes of incubation with LTX-315. (Figure 12).
DISCUSSION
Recent advances in immunotherapy treatment of 
metastatic melanoma has gained much attention lately [24]. 
Especially the overwhelming and lasting clinical response 
in some patients treated with immune checkpoint blockade, 
has been the source of growing optimism and interest in 
the field of cancer immunotherapy [25, 26]. However, 
the response rates in patients with metastatic melanoma 
treated with these new drugs are typically below 40% and 
a significant number of patients experience serious adverse 
effects. [27, 28] More insight into beneficial combinations 
of existing treatments are called for, as well as biomarkers 
for successful patient selections. [29–31] There is also 
interest in new approaches within cancer immunotherapy. 
Host defense peptides (HDPs) are a part of the innate 
immune system [1]. There is a wide range of structural 
diversity between different HDPs, but common features 
are cationicity, amphipatic conformation, and an ability 
to interact with cellular membranes [1, 32]. Some HDPs 
and de novo designed peptides have been shown to exhibit 
anticancer activities in a number of experimental studies 
[3, 33– 35], and the most commonly described mode 
of action is a direct membranolytic effect [36]. Several 
studies of cancer cells from different cancers demonstrate 
that the plasma membrane of malignantly transformed 
cells are different from their normal counterparts with 
regard to overall electrical charge, membrane fluidity 
and cell surface area. These changes makes cancer cells 
more vulnerable and allows for a more selective killing of 
cancer cells as compared to normal cells. Cancer cells are 
known to be more negatively charged than the membranes 
of their normal counterpart cells, due to a higher amount 
of anionic components in the plasma membrane such 
as phosphatidylserine [37–39], proteoglycans with 
heparin sulphate [40–42] and sialic acid on glycoproteins 
(e.g. mucins) [43–45]. These changes may cause cancer 
cells to be vulnerable and allows for a more selective 
killing of cancer cells by cationic peptides as compared 
to normal cells. The naturally occurring peptide LfcinB 
has served as a model peptide for a new group of shorter 
oncolytic peptides [13].
Intratumoral treatment with one of these peptides, 
LTX-315, was shown to induce tumor necrosis and long-
lasting regression in in the majority (80%) of animals 
in a murine B16 melanoma model [15]. Histological 
investigations of treated tumors revealed extensive 
hemorrhagic necrosis and infiltration of CD3+ T cells. 
Moreover, mRNA levels of inflammatory cytokines such 
as IL1β, IL6 and IL18 were found to be augmented in 
the tumor tissue after LTX-315 treatment. The treatment 
did also prevent lung metastasis in mice re-challenged 
with B16F1 cells intravenously [15]. Tumor protective 
immune responses developed by another short oncolytic 
peptide involved both CD4+ and CD8+ T cells (13). 
Taken together these findings demonstrates that oncolytic 
peptides have an ability to stimulate strong T-cell 
dependent protective cancer specific responses. In this 
article, we investigate the mode of action of the oncolytic 
peptide, LTX-315 in more detail in vitro. In vitro studies 
demonstrated that LTX-315-induced cell death in A375 
melanoma cells takes place within minutes after treatment. 
(Figure 2). This stands in contrast to conventional 
cytostatic drugs, which target the cell’s DNA or mitotic 
apparatus, killing dividing cells in a matter of several 
hours or days [46, 47]. In general, HDPs are known to kill 
cancer cells by either plasma membrane attack via pore 
formation or through membrane destabilization, as well 
as by the induction of programmed cell death, independent 
of proliferative status or drug-resistant phenotype [3]. 
The ability to induce loss of plasma membrane integrity 
by penetration or destabilization is a common feature 
within the diverse classes of HDP [2, 3, 34, 48], and 
LTX-315 proved to share this feature as demonstrated 
with PI studies performed with confocal microscopy. 
Cells treated with 35 μM LTX-315 were PI positive after 
5 min, demonstrating a rapid effect against the plasma 
membrane (Figure 4). To determine if the process of 
plasma membrane disruption was temperature dependent, 
parallel experiments at both 4oC and 37oC were performed. 
We observed that LTX-315 was able to disintegrate the 
plasma membrane at low temperature, pointing toward a 
direct interaction with the plasma membrane (Figure 4). 
Confocal and electron microscopy imaging of LTX-315-
treated cells supported a direct membrane effect since a 
majority of the cells treated with a high concentration of 
LTX-315 (17 μM) was killed by a membranolytic mode of 
action (Figures 3, 4). The parental peptide LfcinB has been 
proven to internalize and cause cell death by targeting the 
mitochondria, resulting in both caspase-dependent and 
caspase independent cell death [8, 9, 49]. These findings, 
together with the knowledge that the mitochondria are the 
most negatively charged organelle in the cytoplasm and 
would therefore likely attract any internalized cationic-
charged molecule, led us to investigate whether LTX-315 
was internalized and targeted to the mitochondria. Indeed, 
by labeling with the fluorescent molecule Pacific Blue, 
LTX-315 was shown to be internalized and distributed in 
the cytoplasm. At low concentrations, accumulation of the 
peptide in close proximity to the mitochondria was evident, 
whereas at higher concentrations the peptide was more 
even distributed within the cytoplasm and accumulated in 
circular structures both in association to the mitochondria 
but also closer to the cell membrane (Figure 6A). The 
fluorescence labeled mock sequence peptide LTX-328 was 
not detected intracellularly, proving that internalization is 
specific for LTX-315 and not caused by the fluorescent tag. 
A confocal imaging of the melanoma cells labeled with 
the membrane potential-dependent mitochondrial stain 
Mitotracker CMXh2ROS showed a loss of mitochondrial 
Oncotarget34917www.impactjournals.com/oncotarget
Figure 10: A375 melanoma cells treated with LTX-315 (35 μM) release cytochrome-C into the cell supernatant. Cytochrome-C 
was detected by Elisa assay.
Figure 11: HMGB1 is released in the supernatant after LTX-315 treatment. A375 human melanoma cells were treated with 
35 μM LTX-315 (top) or LTX-328 (bottom), and cell lysate (L) and supernatant (S) were analyzed with western blot. HMGB1 from LTX-
315-treated cells demonstrated a gradual translocation from the cell lysate to the cell supernatant. Control cells were treated with media 
alone, and showed no translocation after 60 minutes.
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signal 60 minutes after peptide treatment (Figure 7), 
indicating that the peptide targets the mitochondria 
membrane and causes a loss of mitochondrial membrane 
potential. Cell morphology studies (TEM) showed 
significant alternations in the mitochondria morphology 
after LTX-315 treatment. Treated cells demonstrated 
less electron-dense mitochondria with a distortion of the 
cristae organization, as well as vacuolization within the 
mitochondria as compared to mitochondria of untreated 
cells (Figure 8 A–8C). Furthermore, vacuolization within 
the cytoplasm was evident in approximately 20% of cells 
treated with 3,5 μM of LTX-315. Hence, these findings 
reveal that the de novo generated LTX-315 peptide is 
internalized and disintegrate the mitochondria.
When the mitochondria are dysfunctional, free 
oxygen radicals (ROS) may be formed [21]. An increased 
ROS formation was detected within a few minutes after 
LTX-315 treatment (Figure 12). However, the fluorometric 
assay used is not specific for mitochondrial ROS and may 
measure other intracellular sources of ROS such as ER 
and peroxisomes [50]. Independent of intracellular source 
an increase in ROS may lead to cell death [51, 52] through 
oxidation of lipids and proteins, as well as DNA damage and 
mitochondrial dysfunction [53]. ROS levels have also been 
linked to cell death by autophagy, a self-catabolic process in 
which the cell engulfs and destroys its own organelles via 
lysosomal proteinase-regulated elimination [53].
DAMPs (Death Associate Molecular Pattern) are 
naturally expressed molecules that signal tissue damage 
to the host. These molecules may be secreted by activated 
macrophages, natural killer (NK) cells or mature dendritic 
cells (DC) in response to inflammatory stimuli such 
as infection or tissue injury, or are released into the 
extracellular compartment by distressed or necrotic cells 
[54]. DAMPs exert strong stimulatory effect on immune 
cells. There are a high number of recognized and suggested 
DAMPs such as High Motility Group Box 1 proteins 
(HMGB1), Adenosine Triphosphate (ATP) [55–59] and 
mitochondrial proteins such as Cytochrome-C and also 
ROS generated by damaged or dysfunctional mitochondria 
[60, 61]. DAMPs can bind to Pattern Recognition 
Receptors (PRRs) on the cell surface or in the cytosol, 
thus leading to pro-inflammatory cytokine production 
and the activation of antigen presenting cells [62]. The 
mitochondria are important mediators of inflammation 
[60, 61, 63, 64] and a source of DAMPs [22, 63, 65, 66]. 
Since LTX-315 treatment affects the mitochondria, its 
ability to induce release of certain mitochondrial derived 
DAMPs such as ATP and Cytochrome-C was investigated.
Increased levels of Cytochrome-C were detected 
in the supernatant of LTX-315 treated cell cultures 
(Figure 10). Cytochrome-C is a mitochondrial protein 
released from the intermembrane space and into the 
cytosol when the outer mitochondrial membrane is 
perturbed. By binding to the apoptotic protease activating 
factor-1 (Apaf-1) it is also a part of the apoptotic cascade 
that eventually leads to cell death by apoptosis. However, 
when cytochrome-C is present in the extracellular space, 
it has been reported to act as a pro-inflammatory mediator, 
thus activating NF-kB and inducing cytokine and 
chemokine production [67]. We also detected increased 
levels of ATP in the supernatant of LTX-315 treated 
cells (Figure 9). When ATP is released extracellularly it 
functions as a DAMP by activating the purinergic P2RX7 
receptors on dendritic cells (DC) [55]. This receptor not 
only functions as a pore that opens for small cationic and 
Figure 12: ROS generation in LTX-315 induced cell death. A375 cells were treated with LTX-315 (17 μM) at different 
concentrations for 30 minutes. After peptide treatment, carboxy-H2DCFDA was added to the samples and fluorescence was analyzed with 
a fluorescence plate reader. The experiment was conducted in duplicate, with bars representing mean fluorescence +- S.D.
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later larger molecules after binding to ATP, its activation 
also causes the processing and release of the pro-
inflammatory cytokine IL-1β [68, 69].
High-Mobility-Group-Box-1 (HMGB1) is a 
non-histone, chromatin-binding nuclear protein. Once 
passively released from necrotic cells, HMGB1 is able 
to trigger the functional maturation of dendritic cells, 
cytokine stimulation and chemotaxis among several 
immunopotentiating effects. HMGB1 is normally present 
in the cell nucleus and would be expected in a cell lysate 
of untreated cells, and not in the culture supernatant. 
[22, 56, 70, 71]. Western blot analysis of treated A375 
cultures showed a translocation of HMGB1 from the 
cellular compartment to the supernatant (Figure 11), thus 
revealing that LTX-315 treatment can cause release of 
non-mitochondrial DAMPs.
Taken together, our data demonstrate that LTX-315 
induces lytic cell death in cancer cells, not only by directly 
attacking the plasma membrane, but also as a result of 
an injury to vital intracellular organelles, particularly 
mitochondria, after the internalization of the peptide at 
concentrations too low to cause an immediate loss of 
plasma membrane integrity. We demonstrate that the 
peptide treatment causes the release of several DAMPs 
such as cytochrome-C, ATP, HMGB1. The DAMPs may 
affect the cellular integrity of the damaged cells in several 
ways, but are also associated with hallmarks of so-called 
immunogenic cell death [72–74]. The excessive release of 
DAMPs may help explain the strong effect of LTX-315 
obtained in experimental animal tumor models, which have 
not only demonstrated a primary tumor regression and 
lymphocyte infiltration, but also protective and systemic 
immune response upon re-challenge with the same tumor 
[14, 15]. The overall strong therapeutic effect may be due 
to the release of tumor-specific antigens released into the 
extracellular compartment, together with potent immune 
stimulatory molecules (DAMPS) such as ATP, cytochrome-C 
and HMGB1. In turn, these will lead to a maturation and 
activation of DCs and other accessory cells of the adaptive 
immune system. Our data unveil the oncolytic effect of 
LTX-315, involving perturbation of both the cell membrane 
and the mitochondria, with subsequent release of DAMPs, 
which highlight the ability of LTX-315 to induce complete 
regression and long-term protective immune responses. 
LTX-315 has a potential as a novel immunotherapeutic agent 




LTX-315 (K-K-W-W-K-K-W-Dip-K-NH2) and 
LTX-328 (K-A-Q-Dip-Q-K-Q-A-W-NH2) were made 
on request by Bachem AG (Bubendorf, Switzerland) 
and Innovagen (Lund, Sweden), respectively. Dip is 
the aromatic non-coded amino acid β-diphenylalanine. 
LTX-315 Pacific Blue and LTX-328 Pacific Blue were 
purchased on request from Innovagen (Lund, Sweden) 
and Norut (Tromsø, Norway), respectively.
Cell culture
The A375 cell line A375 (ECACC, 88113005) 
is a human malignant melanoma derived from patient 
material, and was purchased from Public Health England 
(PHE Culture Collections, Porton Down, Salisbury, 
UK). Cells were maintained as monolayer cultures in 
high glucose 4.5% DMEM supplemented with 10% FBS 
and 1% L-glutamine, but not as antibiotics (complete 
medium). The cell line was grown in a humidified 5% 
CO2 atmosphere at 37°C, and was regularly tested for the 
presence of mycoplasma with MycoAlert (Lonza).
In vitro cytotoxicity
The cytotoxic effect of LTX-315 was investigated 
using the colorimetric MTT viability assay [8, 16, 17]. The 
A375 cells were seeded at a concentration of 1 × 105 cells/
ml in a volume of 0.1 ml in 96-well plates, and allowed to 
adhere in a complete growth medium overnight. The media 
was then removed and the cells were washed twice in 
serum-free, RPMI-1654 medium, before adding LTX-315 
dissolved in serum-free RPMI at concentrations ranging 
from 2-180 μm/ml, and incubated for 5–180 minutes. Cells 
added serum-free RPMI were used as negative control 
cells, while cells treated with 1% Triton X-100 in serum-
free medium were used as a positive control. The results 
were calculated using the mean of three experiments, each 
with triplicate wells.
Confocal microscopy
Live cell imaging with unlabeled cells - A375 cells 
were seeded at 10,000 cells/well in a complete medium 
in Nunc Lab-Tec 8-wells chambered covered glass 
(Sigma) pre-coated with 25 μg/ml human fibronectin 
(Sigma) that were allowed to adhere overnight. Cells 
were washed twice with a serum-free RPMI, treated with 
peptide dissolved in RPMI and investigated using Bright 
Field on a Leica TCS SP5 confocal microscope, with 
a 63X/1.2W objective. The microscope was equipped with 
an incubation chamber with CO2 and temperature control.
Live cells, mitotracker - Cells were seeded as for live 
cell imaging, and treated with Mitotracker CMH2XROS 
(Invitrogen) at 100 nM for 15 minutes prior to peptide 
treatment. Cells were treated with 17 μM LTX-315, with 
negative control serum-free RPMI only. After 60 min of 
incubation, cells were analyzed using a Zeiss microscope 
equipped with an incubation chamber with CO2 and 
temperature control. All confocal imaging experiments were 
subsequently conducted at least twice with similar results.
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Live cell- propidium iodide – A375 cells were 
seeded at 10,000 cells/well in a complete medium in 
Nunc Lab-Tec 8-wells chambered covered glass (Sigma) 
and allowed to adhere 48 hours. Cells were washed 
twice with a serum-free RPMI, treated with 35 μM LTX-
315, propidium iodide (PI) (sigma) and Hoechst33342 
dissolved in RPMI. Incubation time was 5 minutes and 
was performed in regular incubation condition or on ice. 
The media was subsequently replaced with serum free 
RPMI before immediate analyzation using a Zeiss 
confocal microscope equipped with an incubation chamber 
with CO2 and temperature control.
Fixed cells, fluorescence-labeled 
peptide - Subconfluent A375 cells were seeded at 8,000 
cells/well as above, and transfected the second day using 
the Lipofectamine LTX with Plus transfection reagents 
(Invitrogen) following the manufacturer’s protocol. The 
mitochondria were labeled using the pDsRed2-Mito, and 
the nucleus was labeled using the GFP-Histon2B plasmid 
(a kind gift from the Imaging Platform, University of 
Tromsø). A day after transfection, cells were washed 
twice with serum-free RPMI, and treated at different 
concentration and incubation periods with LTX-315 
Pacific Blue or LTX-328 Pacific Blue. LTX-315 PB 
exhibited a similar cytotoxic profile as the unlabeled 
LTX-315 as determined by MTT assay. Control cells were 
treated with unlabeled LTX-315 and also with serumfree 
RPMI only. After incubation, cells were fixed with 4% 
paraformaldehyde in PBS, and the wells were covered 
with Prolong Gold antifade (Invitrogen). Cells were further 
analyzed by use of a Leica TCS SP5 confocal microscope, 
with a 693, 1.2 W objective. Pacific Blue, GFP and Ds 
Red were excited using UV, with 488 and 561 lasers, 
and fluorescence channels were sequentially detected 
using the following band passes: UV: 420–480 nm (with 
attenuation), 488: 501–550 nm and 561: 576–676 nm.
TEM electron microscopy
A375 cells were seeded at 1 × 105 cells per well in 
6-well plates and allowed to grow for three days to optimize 
membrane structures in the culture, and the medium was 
changed on the second day. Cells were washed twice in 
serum-free RPMI before being treated with LTX-315 
dissolved in serum-free RPMI at 3.5 and 17 μM, with serum-
free RPMI as a negative control. Cells were then washed 
with PBS before fixation for 24 hours at 4°C with 4% 
formal aldehyde and 1% gluteralaldehyde in a Hepes buffer 
at pH 7.8. Dehydration and post-fixation protocols included 
incubation in a 5% buffered tannic acid and incubation in 
1% osmium-reduced ferrocyanide. Ultrathin sections were 
prepared, and uranyl acetate (5%) and Reynolds’s lead 
citrate were used for staining and contrasting. Samples 
were examined on a JEOL JEM-1010 transmission 
electron microscope, and images were taken with an 
Olympus Morada side-mounted TEM CCD camera 
(Olympus soft imaging solutions, GmbH, Germany).
Fluorescence measurement of reactive oxygen 
species (ROS)
A DCFDA cellular reactive oxygen species 
detection assay kit was purchased from Abcam® (UK), 
and A375 cells seeded in a 96-well Costar black clear 
bottom plate with 20,000 cells per well incubated in 
37°C 16 hours prior to DCFDA assay. Cells were washed 
with a 100 μL/well of pre-warmed PBS one time, and 
incubated with 20 μM of DCFDA in a buffer solution 
supplied with the kit at 37°C in a cell culture incubator 
for 45 min, and then washed again with a buffer solution 
of 100 μL/well. The cells were subsequently incubated 
with a 100 μL/well LTX-315 peptide dissolved in HBSS 
buffer solution at concentrations of 17 μM for 30 min, 
and untreated cells were used as a negative control. The 
fluorescence intensity was determined at an excitation 
wavelength of 485 nm and an emission wavelength of 
530 nm on a FLUOstar Galaxy plate reader.
Release of high mobility-group box-1 (HMGB1)
A375 cells were seeded with 3 × 10 5cells/well in 
6-well plates in complete medium, and allowed to adhere 
overnight. Cells were treated with LTX-315 or LTX-328 
at 35 μM, and incubated at 37oC and 5% CO2 for different 
time points (5, 10, 15, 30, 60 min), and negative controls 
were serum-free RPMI-1650. Supernatants (S) were 
collected and centrifuged at 1,400 g for five minutes, 
and cell lysates (L) were harvested after washing with 
PBS twice and thereafter lysed using a 4X Sample 
buffer (Invitrogen), 0.1M DTT (Sigma) and water. 
Supernatants were concentrated using Amicon Ultra 
50 K centrifugal filters (Millipore UFC505024), and the 
cell lysate was sonicated. Both supernatants and lysate 
were boiled and resolved by 10% sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE), and then 
electro transferred to a polyvindiline difluoride (PVDF) 
membrane (Millipore). The membrane was blocked in 5% 
skimmed milk and incubated with the HMGB1 antibody 
(rabbit, polyclonal, Abcam ab 18256); the membrane 
was then rinsed several times with TBST, incubated with 
a horseradish peroxidase (HRP)-conjugated secondary 
antibody (Abcam ab6721), rinsed again with TBST and 
finally developed using WB Luminol Reagent (Santa Cruz 
Biotechnology, Heidelberg, Germany).
Release of cytochrome-C
A375 cells were seeded as in HMGB1 studies, 
and treated with 35 μM LTX-315 for different time 
points (5, 15, 45 min). Supernatants were collected and 
concentrated as with HMGB1 studies, and samples from 
the supernatants were analyzed using a 4.5-hour solid 
form Cytochrome C- Elisa kit (R&D Systems, USA, 
#DCTC0) following the manufacturer’s instructions. 
Shortly thereafter, a 50% diluted sample was analyzed 
Oncotarget34921www.impactjournals.com/oncotarget
and the optical density was determined using a microplate 
reader set at 450 nm. This reading was then subtracted 
from the reading at 540 nm. A standard curve was 
generated for each set of samples assayed. Samples were 
run in four parallels, and the cytochrome-C released into 
the supernatant was expressed as a fold over the level of 
cytochrome-C in the supernatant of untreated cells.
Release of ATP
The supernatant of LTX-315-treated A375 cells 
was analyzed using an Enliten ATP luciferase assay kit 
(Promega, USA). Cells were seeded as described for ROS 
assay, and treated with LTX-315 (35 μM) for 1–15 minutes; 
each experiment was performed with two parallels and 
conducted three times. Negative controls were untreated 
A375 cells exposed to serum-free medium alone. Samples 
diluted 1:10 were analyzed with a Luminoscan RT 
luminometer according to the manufacturer’s protocol.
Statistical analysis
All data represent at least two independent 
experiments with at least two parallels, which were expressed 
as the mean ± SD. Cytochrome-C were conducted twice 
with four parallels. ATP luciferase assay was conducted three 
times with two parallels. ROS assay were conducted twice 
with two parallels. Cytochrome-C release and ATP release 
data was compared using one-way ANOVA and a multiple 
comparison test (Tukeys Multiple Comparison Test), and we 
considered the P-value < 0.05 statistical significant.
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